"We found out the using IRIS intraoperatively during partial nephrectomy does help us with preserving renal parenchyma," says Teona Iarajuli.
In this video, Teona Iarajuli discusses the background and findings from her study, “Does utilizing IRIS, a segmented three-dimensional model, preserve renal parenchymal volume during robotic partial nephrectomy?”, which was presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Iarajuli is a fourth year medical student at Hackensack Meridian School of Medicine in New Jersey.
Video Transcript:
Could you describe the background for this study?
IRIS is a 3D anatomical model that is interactive, and it's actually made out of CT scans. It gives you an ability to rotate and directly pull the tumor out of the kidney during the surgery. It gives you a much better visual field during partial nephrectomy. So, our goal in our study was to find out does IRIS actually help us to preserve renal parenchyma in high nephrometry score complicated cases during partial nephrectomy.
What were some of the notable findings?
We found out the using IRIS intraoperatively during partial nephrectomy does help us with preserving renal parenchyma via making the surgery more precise, compared to non-IRIS patients. I just want to emphasize that using this 3D model of IRIS does have a potential to improve patient outcomes post-partial nephrectomy, especially by preserving more renal parenchyma and also just making the surgery much more precise than without IRIS.
This transcription has been edited for clarity.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.